Revita Life Sciences

Diabetes

Type 1 diabetes, also called juvenile diabetes, is an autoimmune disease that frequently presents itself from infancy to the late 30s For unknown reasons, the immune system sometimes launches an attack against the body’s own insulin-producing beta cells and destroys them. Nearly complete B-cell loss does characterize the final stages of the IDDM.

Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder of Insulin Resistance followed by Progressive and Inexorable β-cell dysfunction. The ultimate pathology is a failure of the pancreas to produce a sufficient amount of insulin to appropriately regulate glucose levels in the body.  At the time of diagnosis, almost 50% of β-cell mass is lost.

“TYPE 1 AND TYPE 2 DIABETES RESULT ENTIRELY OR IN PART FROM INADEQUATE NUMBERS OF NORMALLY FUNCTIONING PANCREATIC BETA CELLS.

IT THEREFORE FOLLOWS THAT RESTORATION OF NORMAL BETA CELL MASS AND FUNCTION SHOULD BE A VIABLE SOLUTION.”

Mesenchymal stem cells facilitate regeneration of pancreatic beta cells probably recruitment of progenitors of insulin-producing beta cells. MSCs also ameliorate Insulin Resistance  and  exert immunomodulatory effects.

How It Is Done

As a day care procedure 120 ml of Bone marrow and 200 ml of fat is aspirated and processed in a closed system for stem cells isolation. 2 ml volume having at least 2-4 million stem cells per kg body weight is injected either into

Allogenic umbilical cord derived MScs may be needed in few cases

  • Intravenous
  • Into the feeding artery of pancreatic tail

What To Expect

Type 1 diabetes

  • 60 % pf patients show improvements
  • 40% decrease in insulin requirement in first 3 months
  • 60% dose decrement in the next 6 months
  • 65% dose decrement in the next 9 months
  • 55% dose decrement in the next 12 months
  • Simulated C peptide increased proportionately
  • 60% patients could maintain HbA1c <7 HbA1c
  • One Patient Insulin free (at 15 months )

Type 2 diabetes

  • Overall, 80% patients show significant response over 2 years
  • 20% decrease in insulin req in the first 3 months
  • 29% dose decrement AT 6 months
  • 52% dose decrement AT 12 months
  • 35% dose decrement AT 24 months
  • 80% patients could maintain HbA1c between 6-7 months
  • 12% of patients are able to discontinue insulin completely & only on oral drugs upto 2years
  • Insulin level basal and after meal improved by 60 % .
  • Stimulated C peptide levels increased proportionately and positively corelated with decrease in Insulin Requirement.